TP
CSTL icon

TritonPoint Partners’s Castle Biosciences CSTL Stock Holding History

TritonPoint Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Buy
10,796
+19
+0.2% +$423 0.02% 311
2026
Q1 		$265K Hold
10,777
– – 0.1% 173
2025
Q4 		$419K Buy
+10,777
New +$347K 0.22% 105

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TritonPoint Partners's CSTL Position: Q2 2026 in Review

TritonPoint Partners increased its Castle Biosciences (CSTL) stake by 0.18% in Q2 2026, buying an estimated $423 and bringing the position to 10,796 shares worth $257K. The position accounts for 0.02% of the portfolio, ranked #311.

TritonPoint Partners first reported a position in CSTL in Q4 2025 and has held it in 3 quarters since. The position peaked at $419K in Q4 2025. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • TritonPoint Partners held 10,796 shares of Castle Biosciences worth $257K as of Q2 2026.
  • TritonPoint Partners bought 19 Castle Biosciences shares in Q2 2026, an estimated $423.
  • Castle Biosciences made up 0.02% of TritonPoint Partners's portfolio in Q2 2026, its #311 holding.
  • TritonPoint Partners first reported a position in Castle Biosciences in Q4 2025 and has held it in 3 quarters since.
  • TritonPoint Partners's Castle Biosciences position peaked at $419K in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on TritonPoint Partners's 13F filing for Q2 2026, filed 13 Aug 2026.